{"protocolSection":{"identificationModule":{"nctId":"NCT02849509","orgStudyIdInfo":{"id":"1160.261"},"organization":{"fullName":"Boehringer Ingelheim","class":"INDUSTRY"},"briefTitle":"Patient Convenience Study- NIS RELATE","officialTitle":"Non-interventional Study Describing Patients' Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamin K Antagonist for Stroke Prophylaxis in Atrial Fibrillation."},"statusModule":{"statusVerifiedDate":"2019-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-06-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-12-30","type":"ACTUAL"},"completionDateStruct":{"date":"2017-12-30","type":"ACTUAL"},"studyFirstSubmitDate":"2016-05-04","studyFirstSubmitQcDate":"2016-07-26","studyFirstPostDateStruct":{"date":"2016-07-29","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-12-12","resultsFirstSubmitQcDate":"2019-04-18","resultsFirstPostDateStruct":{"date":"2019-07-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-04-18","lastUpdatePostDateStruct":{"date":"2019-07-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Boehringer Ingelheim","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa® to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its approved indication in the approved dosages of 110 mg or 150 mg twice daily) in comparison to standard care using Vitamin K Antagonist (VKA)."},"conditionsModule":{"conditions":["Atrial Fibrillation"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":1313,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Switch Patients / A","description":"Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.","interventionNames":["Drug: Pradaxa (dabigatran)"]},{"label":"New Patients / B","description":"Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).","interventionNames":["Drug: Vitamin K antagonist"]}],"interventions":[{"type":"DRUG","name":"Pradaxa (dabigatran)","description":"Pradaxa (dabigatran etexilate)110mg or 150mg","armGroupLabels":["Switch Patients / A"]},{"type":"DRUG","name":"Vitamin K antagonist","description":"Vitamin K antagonist or Pradaxa","armGroupLabels":["New Patients / B"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Mean Perception of Anticoagulant Treatment Questionnaire, Part 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second Assessment Compared to Baseline Assessment","description":"Mean Perception of Anticoagulant treatment Questionnaire, part 2 (PACT-Q2) scores, for patients in cohort A, at second assessment compared to baseline assessment. The PACT-Q2 is composed of 3 dimensions covering: convenience (11 items), burden of disease \\& treatment (2 items), \\& anticoagulant treatment satisfaction (7 items). In this outcome the mean convenience \\& satisfaction dimension scores of PACT-Q2 at second assessment (Visit 2) were compared with baseline assessment (Visit 1). Within the PACT-Q2, items for convenience \\& for burden of disease and treatment were reversed (reversed score = 6 - item score), added together \\& rescaled on a 0-100 scale to obtain the convenience dimension score. Items for anticoagulant treatment satisfaction were summed \\& rescaled on 0-100 scale to determine satisfaction score. High scores are more favorable.\n\nPACT-Q2 which were completed more than 1 day after discontinuation of treatment or using incorrect procedure were excluded from analysis.","timeFrame":"Visit 1 (Baseline) and second assessment Visit 2 (7-124 days after initiation on Pradaxa or VKA)"},{"measure":"Mean PACT-Q2 Scores, for Patients in Cohort A, at Last Assessment Compared to Baseline Assessment","description":"Mean PACT-Q2 scores, for patients in cohort A, at last assessment compared to baseline assessment. The mean convenience and satisfaction dimension scores of PACT-Q2 at the last assessment (Visit 3) were compared with the baseline assessment (Visit 1). Within the PACT-Q2, items for convenience and for burden of disease and treatment were reversed (reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score. Items for anticoagulant treatment satisfaction were summed and rescaled on a 0-100 scale to determine the satisfaction score. High scores are more favorable.\n\nPACT-Q2 which were completed more than 1 day after discontinuation of treatment or using incorrect procedure were excluded from the analysis.","timeFrame":"Visit 1 (Baseline) and last assessment Visit 3 (125-365 days after initiation on Pradaxa or VKA)"},{"measure":"Mean PACT-Q2 Scores, for Patients in Cohort B, at Second Assessment Compared Between Treatment Groups","description":"Mean PACT-Q2 scores, for patients in cohort B, at second assessment compared between treatment groups. Convenience dimension score and satisfaction dimension score of PACT-Q2 both range from 0 to 100 with high scores indicate better outcome.\n\nMean PACT-Q2 scores, for patients in Cohort B, were compared between matched Pradaxa® and VKA patients at the second assessment. The mean convenience and satisfaction scores of PACT-Q2 were compared between matched Pradaxa® and VKA patients. Pradaxa® and VKA patients were matched based on propensity scores using a variable ratio, parallel, balanced 2:1, nearest neighbour matching algorithm with a caliper width of 0.05 and without replacement.\n\nPACT-Q2 which were completed more than 1 day after discontinuation of treatment or using incorrect procedure were excluded from the analysis.","timeFrame":"Second assessment Visit 2 (7-124 days after initiation on Pradaxa or VKA)"},{"measure":"Mean PACT-Q2 Scores, for Patients in Cohort B, at Last Assessment Compared Between Treatment Groups","description":"Mean PACT-Q2 scores, for patients in cohort B, at last assessment compared between treatment groups.\n\nConvenience dimension score and satisfaction dimension score of PACT-Q2 both range from 0 to 100 with high scores indicate better outcome.\n\nMean PACT-Q2 scores, for patients in Cohort B, were compared between matched Pradaxa® and VKA patients at the last assessment. The mean convenience and satisfaction scores of PACT-Q2 were compared between matched Pradaxa® and VKA patients. Pradaxa® and VKA patients were matched based on propensity scores using a variable ratio, parallel, balanced 2:1, nearest neighbour matching algorithm with a caliper width of 0.05 and without replacement.","timeFrame":"Last assessment - Visit 3 (125-365 days after initiation on Pradaxa or VKA)"},{"measure":"Patient Characterization at Baseline - Categorical Parameters","description":"Categorical parameters of the patient characteristics at baseline included age, gender, Stroke- and/or bleeding related risk factors in medical history (MH), co-morbidities (CoMo), concomitant therapies (CM) and dosing of Pradaxa® (DoP).","timeFrame":"Baseline (Visit1)"},{"measure":"Patient Characteristics at Baseline - Duration of Previous VKA Treatment for Cohort A","description":"Duration of continuous VKA treatment for stroke prevention prior to baseline assessment (Cohort A)","timeFrame":"Baseline (Visit1)"}],"secondaryOutcomes":[{"measure":"Patient Characteristics at Baseline - CHA2DS2-VASc Stroke Risk Score","description":"CHA2DS2-VASc stroke risk score is calculated based on the following conditions: Congestive heart failure, Hypertension, Age (≥ 75), Diabetes Mellitus, Stroke/ Transient Ischaemic Attack (TIA), Vascular disease, Age 65-74, Sex category.\n\nCHA2DS2-VASc stroke risk score may range from 0 to 9 with 0 being the best outcome.","timeFrame":"Baseline (Visit1)"},{"measure":"Patient Characteristics at Baseline - HAS-BLED Bleeding Risk Score","description":"HAS-BLED bleeding risk score is calculated based on the following conditions: Hypertension, Abnormal renal and Hypertension, Abnormal renal and liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly (\\>65 years), Drugs and Alcohol.\n\nHAS-BLED bleeding risk score may range from 0 to 9 with 0 being the best outcome.","timeFrame":"Baseline (Visit1)"},{"measure":"Patient Characteristics at Baseline - Creatinine Clearance","description":"Creatinine clearance at baseline is a measure of the patient's kidney function and is one of the baseline patient characteristics.","timeFrame":"Baseline (Visit1)"},{"measure":"Mean PACT-Q2 Scores, for Patients in Cohort A, at Last Assessment Compared to Second Assessment","description":"Mean PACT-Q2 scores, for patients in cohort A, at last assessment compared to second assessment.\n\nThe PACT-Q2 is composed of 3 dimensions covering: convenience (11 items), burden of disease and treatment (2 items), and anticoagulant treatment satisfaction (7 items).\n\nThe mean convenience and satisfaction dimension scores of PACT-Q2 at the last assessment (Visit 3)were compared with the second assessment (Visit 2). Within the PACT-Q2, items for convenience and for burden of disease and treatment were reversed (reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score. Items for anticoagulant treatment satisfaction were summed and rescaled on a 0-100 scale to determine the satisfaction score.","timeFrame":"Second assessment - Visit 2 (7-124 days after initiation on Pradaxa or VKA) and last assessment - Visit 3 (125-365 days after initiation on Pradaxa or VKA)"},{"measure":"Description of Perception of Anticoagulant Treatment Questionnaire, Part 1 (PACT-Q1) Items at Baseline for Cohort B","description":"For Cohort B, scores of PACT-Q1 at baseline were summarised descriptively.\n\nThe PACT-Q1 is composed of a single dimension (7 items) covering the expectations of patients regarding their anticoagulant treatment and is to be administered before treatment initiation.\n\nThe PACT-Q1 scores ranged from 1 (Not at all) to 5 (Extremely/Completely/ Very much).","timeFrame":"Baseline (Visit1)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\nCohort A:\n\n1. A. Written informed consent prior to participation\n2. A. Female and male patients \\>= 18 years of age with a diagnosis of non-valvular atrial fibrillation.\n3. A. At least 3 months of continuous VKA treatment for stroke prevention prior to baseline assessment.\n4. A. Patients switched to Pradaxa® according Summary of Product Characteristics and physician's discretion.\n\nOR\n\nCohort B:\n\n1. B. Written informed consent prior to participation.\n2. B. Female and male patients \\>= 18 years of age newly diagnosed with non-valvular atrial fibrillation and no previous treatment for stroke prevention (no use of any oral anticoagulant (OAC) within one year prior to enrolment).\n3. B. Stroke prevention treatment initiated with Pradaxa® or VKA according to Summary of Product Characteristics and physician's discretion.\n\nExclusion criteria:\n\n1. Contraindication to the use of Pradaxa® or VKA as described in the Summary of Product Characteristics (SmPC).\n2. Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in atrial fibrillation.\n3. Current participation in any clinical trial of a drug or device.\n4. Current participation in an European registry on the use of oral anticoagulation in AF.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"SEASK Patients with Non valvuar Atrial Fribrillation","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Boehringer Ingelheim","affiliation":"Boehringer Ingelheim","role":"STUDY_CHAIR"}],"locations":[{"facility":"Harapan Kita National Cardiovascular Center","city":"Jakarta Barat","zip":"11420","country":"Indonesia"},{"facility":"Rumah Sakit Bina Waluya","city":"Jakarta Timur","zip":"13750","country":"Indonesia"},{"facility":"Rumah Sakit Siloam Lippo Karawaci, Tangerang","city":"Tangerang","zip":"15811","country":"Indonesia","geoPoint":{"lat":-6.17806,"lon":106.63}},{"facility":"Korea University Ansan Hospital","city":"Ansan","zip":"136-705","country":"Korea, Republic of","geoPoint":{"lat":37.32361,"lon":126.82194}},{"facility":"Sejong General Hospital","city":"Bucheon","zip":"422-711","country":"Korea, Republic of","geoPoint":{"lat":37.49889,"lon":126.78306}},{"facility":"Inje University Busan Paik Hospital","city":"Busan","zip":"47392","country":"Korea, Republic of","geoPoint":{"lat":35.10278,"lon":129.04028}},{"facility":"Dong-A University Hospital","city":"Busan","zip":"49201","country":"Korea, Republic of","geoPoint":{"lat":35.10278,"lon":129.04028}},{"facility":"Pusan National Univ. Hosp","city":"Busan","zip":"602-739","country":"Korea, Republic of","geoPoint":{"lat":35.10278,"lon":129.04028}},{"facility":"Soon Chun Hyang University Hospital Cheonan","city":"Cheonan","zip":"31151","country":"Korea, Republic of","geoPoint":{"lat":36.8065,"lon":127.1522}},{"facility":"Dankook University Hospital","city":"Cheonan","zip":"330-715","country":"Korea, Republic of","geoPoint":{"lat":36.8065,"lon":127.1522}},{"facility":"Daegu Catholic University Medical Center","city":"Daegu","zip":"42472","country":"Korea, Republic of","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Keimyung University Dongsan Medical Center","city":"Daegu","zip":"700-712","country":"Korea, Republic of","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Kyungpook National Univ. Hosp","city":"Daegu","zip":"700-721","country":"Korea, Republic of","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Yeungnam University Medical Center","city":"Daegu","zip":"705-703","country":"Korea, Republic of","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Chungnam National University Hospital","city":"Daejoen","zip":"301721","country":"Korea, Republic of"},{"facility":"Chonnam National University Hospital","city":"Gwangju","zip":"501-757","country":"Korea, Republic of","geoPoint":{"lat":35.15472,"lon":126.91556}},{"facility":"Chosun University Hospital","city":"Gwangju","zip":"61453","country":"Korea, Republic of","geoPoint":{"lat":35.15472,"lon":126.91556}},{"facility":"Wonkwang University School of Medicine &amp;amp; Hospital","city":"Iksan","zip":"570-711","country":"Korea, Republic of","geoPoint":{"lat":35.94389,"lon":126.95444}},{"facility":"Inha University Hospital","city":"Incheon","zip":"400 711","country":"Korea, Republic of","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Gachon University Gil Medical Center","city":"Incheon","zip":"405-760","country":"Korea, Republic of","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Jeju National University Hospital","city":"Jeju","zip":"690-767","country":"Korea, Republic of","geoPoint":{"lat":33.50972,"lon":126.52194}},{"facility":"Chonbuk National University Hospital","city":"Jeonju","zip":"561-712","country":"Korea, Republic of","geoPoint":{"lat":35.82194,"lon":127.14889}},{"facility":"Gyeongsang National University Hospital","city":"Jinju","zip":"660-702","country":"Korea, Republic of","geoPoint":{"lat":35.19278,"lon":128.08472}},{"facility":"Seoul National University Bundang Hospital","city":"Seongnam","zip":"463-707","country":"Korea, Republic of","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"The Catholic University of Korea, Seoul St.Mary's Hospital","city":"Seoul","zip":"06591","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul National University Hospital","city":"Seoul","zip":"110-744","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Severance Hospital, Yonsei University Health System","city":"Seoul","zip":"120-752","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"VHS Medical Center","city":"Seoul","zip":"134-791","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Center","city":"Seoul","zip":"135-710","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Gangnam Severance Hospital","city":"Seoul","zip":"135-720","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Korea University Anam Hospital","city":"Seoul","zip":"136-705","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Korea University Guro Hospital","city":"Seoul","zip":"152-703","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Chung-Ang University Hospital","city":"Seoul","zip":"156-755","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Ewha Womans University Mokdong Hospital","city":"Seoul","zip":"158-710","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Ajou University Hospital","city":"Suwon","zip":"443-380","country":"Korea, Republic of","geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"Wonju Severance Christian Hosp","city":"Wonju","zip":"220-701","country":"Korea, Republic of","geoPoint":{"lat":37.35139,"lon":127.94528}},{"facility":"Hospital Sultanah Bahiyah","city":"Alor Setar","zip":"05460","country":"Malaysia","geoPoint":{"lat":6.12104,"lon":100.36014}},{"facility":"Institut Jantung Negara","city":"Kuala Lumpur","zip":"50400","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"facility":"Hospital University Kebangsaan Malaysia","city":"Kuala Lumpur","zip":"56000","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"facility":"University Malaya Medical Centre","city":"Kuala Lumpur","zip":"59100","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"facility":"Hospital Tengku Ampuan Afzan","city":"Kuantan","zip":"25100","country":"Malaysia","geoPoint":{"lat":3.8077,"lon":103.326}},{"facility":"UiTM Sg Buloh Campus","city":"Sg Buloh","zip":"47000","country":"Malaysia"},{"facility":"National Heart Center","city":"Singapore","zip":"169609","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Changi General Hospital","city":"Singapore","zip":"529889","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Bhumibol Adulyadej Hospital","city":"Bangkok","zip":"10220","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"King Chulalongkorn Hospital","city":"Bangkok","zip":"10330","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Pramongkutklao Hospital","city":"Bangkok","zip":"10400","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Ramathibodi Hospital","city":"Bangkok","zip":"10400","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Chiangmai University","city":"Chiangmai","zip":"50200","country":"Thailand","geoPoint":{"lat":18.79038,"lon":98.98468}},{"facility":"Thammasat University Hospital","city":"Pathum Tani","zip":"12120","country":"Thailand"}]},"referencesModule":{"references":[{"pmid":"34857666","type":"DERIVED","citation":"Lee YS, Oh YS, Choi EK, Chern AKC, Jiampo P, Chutinet A, Hanafy DA, Trivedi P, Zhai D. Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study. Open Heart. 2021 Dec;8(2):e001745. doi: 10.1136/openhrt-2021-001745."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Cohort A (Switch Patients - Pradaxa)","description":"Patients with non-valvular atrial fibrillation (NVAF), who were treated with a Vitamin K Antagonist (VKA) therapy for at least 3 months for stroke prevention and then switched to 110 or 150 milligram (mg) twice daily dose of Pradaxa."},{"id":"FG001","title":"Cohort B (New Patients - Pradaxa)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on 110 or 150 mg twice daily Pradaxa"},{"id":"FG002","title":"Cohort B (New Patients - VKA)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on VKA therapy. The choice of vitamin K antagonist and the appropriate dosing was at the discretion of the physician."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"379"},{"groupId":"FG001","numSubjects":"591"},{"groupId":"FG002","numSubjects":"343"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Not prematurely discontinued from Pradaxa or VKA","numSubjects":"289"},{"groupId":"FG001","comment":"Not prematurely discontinued from Pradaxa or VKA","numSubjects":"425"},{"groupId":"FG002","comment":"Not prematurely discontinued from Pradaxa or VKA","numSubjects":"258"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"90"},{"groupId":"FG001","numSubjects":"166"},{"groupId":"FG002","numSubjects":"85"}]}],"dropWithdraws":[{"type":"Worsening of disease under study","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Worsening of other pre-existing disease","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Other adverse event","reasons":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"41"},{"groupId":"FG002","numSubjects":"8"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"12"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"67"},{"groupId":"FG002","numSubjects":"36"}]},{"type":"Other, reason not specified","reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"29"},{"groupId":"FG002","numSubjects":"25"}]},{"type":"No inform. on termination of Pradaxa/VKA","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries.","groups":[{"id":"BG000","title":"Cohort A (Switch Patients - Pradaxa)","description":"Patients with non-valvular atrial fibrillation (NVAF), who were treated with a Vitamin K Antagonist (VKA) therapy for at least 3 months for stroke prevention and then switched to 110 or 150 milligram (mg) twice daily dose of Pradaxa."},{"id":"BG001","title":"Cohort B (New Patients - Pradaxa)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on 110 or 150 mg twice daily Pradaxa"},{"id":"BG002","title":"Cohort B (New Patients - VKA)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on VKA therapy. The choice of vitamin K antagonist and the appropriate dosing was at the discretion of the physician."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"379"},{"groupId":"BG001","value":"591"},{"groupId":"BG002","value":"343"},{"groupId":"BG003","value":"1313"}]}],"measures":[{"title":"Age, Continuous","populationDescription":"The population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"379"},{"groupId":"BG001","value":"591"},{"groupId":"BG002","value":"343"},{"groupId":"BG003","value":"1313"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"69.7","spread":"9.0"},{"groupId":"BG001","value":"67.3","spread":"9.8"},{"groupId":"BG002","value":"63.4","spread":"10.9"},{"groupId":"BG003","value":"67.0","spread":"10.2"}]}]}]},{"title":"Age, Customized","populationDescription":"The population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"379"},{"groupId":"BG001","value":"591"},{"groupId":"BG002","value":"343"},{"groupId":"BG003","value":"1313"}]}],"categories":[{"title":"< 65 Years","measurements":[{"groupId":"BG000","value":"95"},{"groupId":"BG001","value":"196"},{"groupId":"BG002","value":"184"},{"groupId":"BG003","value":"475"}]},{"title":">= 65 and < 75 Year","measurements":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"256"},{"groupId":"BG002","value":"101"},{"groupId":"BG003","value":"511"}]},{"title":">= 75 Years","measurements":[{"groupId":"BG000","value":"130"},{"groupId":"BG001","value":"139"},{"groupId":"BG002","value":"58"},{"groupId":"BG003","value":"327"}]}]}]},{"title":"Sex: Female, Male","populationDescription":"The population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"379"},{"groupId":"BG001","value":"591"},{"groupId":"BG002","value":"343"},{"groupId":"BG003","value":"1313"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"130"},{"groupId":"BG001","value":"228"},{"groupId":"BG002","value":"106"},{"groupId":"BG003","value":"464"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"249"},{"groupId":"BG001","value":"363"},{"groupId":"BG002","value":"237"},{"groupId":"BG003","value":"849"}]}]}]},{"title":"Race and Ethnicity Not Collected","populationDescription":"Race and Ethnicity were not collected from any participant.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}],"categories":[{"measurements":[{"groupId":"BG003","value":"0"}]}]}]},{"title":"Region of Enrollment","description":"Non-South Korea includes four countries, and they are Indonesia, Malaysia, Singapore, and Thailand.","populationDescription":"The population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Korea, Republic Of","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"379"},{"groupId":"BG001","value":"591"},{"groupId":"BG002","value":"343"},{"groupId":"BG003","value":"1313"}]}],"categories":[{"title":"Non-South Korea","measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"32"},{"groupId":"BG003","value":"210"}]},{"title":"South Korea","measurements":[{"groupId":"BG000","value":"325"},{"groupId":"BG001","value":"467"},{"groupId":"BG002","value":"311"},{"groupId":"BG003","value":"1103"}]}]}]},{"title":"Type of hospital or practice","description":"Type of hospital or practice (Healthcare system characteristics)","populationDescription":"The population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"379"},{"groupId":"BG001","value":"591"},{"groupId":"BG002","value":"343"},{"groupId":"BG003","value":"1313"}]}],"categories":[{"title":"Public","measurements":[{"groupId":"BG000","value":"171"},{"groupId":"BG001","value":"255"},{"groupId":"BG002","value":"133"},{"groupId":"BG003","value":"559"}]},{"title":"Private","measurements":[{"groupId":"BG000","value":"200"},{"groupId":"BG001","value":"309"},{"groupId":"BG002","value":"201"},{"groupId":"BG003","value":"710"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"44"}]}]}]},{"title":"Owner of medical practice","description":"Owner of medical practice (Healthcare system characteristics)","populationDescription":"The population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"379"},{"groupId":"BG001","value":"591"},{"groupId":"BG002","value":"343"},{"groupId":"BG003","value":"1313"}]}],"categories":[{"title":"Physician or physician group","measurements":[{"groupId":"BG000","value":"174"},{"groupId":"BG001","value":"268"},{"groupId":"BG002","value":"162"},{"groupId":"BG003","value":"604"}]},{"title":"Health Maintenance Organisation (HMO)","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Community health center","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"10"}]},{"title":"Medical / academic health center","measurements":[{"groupId":"BG000","value":"156"},{"groupId":"BG001","value":"231"},{"groupId":"BG002","value":"144"},{"groupId":"BG003","value":"531"}]},{"title":"Other hospital","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"35"},{"groupId":"BG003","value":"100"}]},{"title":"Other health care corporation","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"68"}]}]}]},{"title":"Speciality of treating physician","description":"Speciality of treating physician (Healthcare system characteristics)","populationDescription":"The population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"379"},{"groupId":"BG001","value":"591"},{"groupId":"BG002","value":"343"},{"groupId":"BG003","value":"1313"}]}],"categories":[{"title":"Cardiologist","measurements":[{"groupId":"BG000","value":"362"},{"groupId":"BG001","value":"572"},{"groupId":"BG002","value":"323"},{"groupId":"BG003","value":"1257"}]},{"title":"General practitioner","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"}]},{"title":"Other specialist","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"52"}]}]}]},{"title":"Baseline creatinine clearance category","populationDescription":"The population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"379"},{"groupId":"BG001","value":"591"},{"groupId":"BG002","value":"343"},{"groupId":"BG003","value":"1313"}]}],"categories":[{"title":"<30 mL/min","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"13"}]},{"title":"30 to <50 mL/min","measurements":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"29"},{"groupId":"BG003","value":"159"}]},{"title":"50 to <80 mL/min","measurements":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"210"},{"groupId":"BG002","value":"78"},{"groupId":"BG003","value":"414"}]},{"title":">=80 mL/min","measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"140"},{"groupId":"BG002","value":"69"},{"groupId":"BG003","value":"278"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"120"},{"groupId":"BG001","value":"175"},{"groupId":"BG002","value":"154"},{"groupId":"BG003","value":"449"}]}]}]},{"title":"CHA2DS2-VASc score","description":"CHA2DS2-VASc score: Congestive heart failure, Hypertension, Age (≥ 75), Diabetes mellitus, Stroke/Transient Ischaemic Attack (TIA), Vascular disease, Age 65-74, Sex category. CHA2DS2-VASc stroke risk score may range from 0 to 9 with 0 being the best outcome.","populationDescription":"The population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"379"},{"groupId":"BG001","value":"591"},{"groupId":"BG002","value":"343"},{"groupId":"BG003","value":"1313"}]}],"categories":[{"title":"Low risk (score=0)","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"84"}]},{"title":"Intermediate risk (score=1)","measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"78"},{"groupId":"BG002","value":"106"},{"groupId":"BG003","value":"227"}]},{"title":"High risk (score ≥2)","measurements":[{"groupId":"BG000","value":"331"},{"groupId":"BG001","value":"482"},{"groupId":"BG002","value":"187"},{"groupId":"BG003","value":"1000"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}]}]},{"title":"HAS-BLED score","description":"HAS-BLED score: Hypertension, Abnormal renal and liver function, Stroke, Bleeding history or predisposition, Labile International Normalized Ratio (INR), Elderly (\\>65 years), Drugs and Alcohol. HAS-BLED bleeding risk score may range from 0 to 9 with 0 being the best outcome.","populationDescription":"The population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"379"},{"groupId":"BG001","value":"591"},{"groupId":"BG002","value":"343"},{"groupId":"BG003","value":"1313"}]}],"categories":[{"title":"Low risk (score <3)","measurements":[{"groupId":"BG000","value":"291"},{"groupId":"BG001","value":"540"},{"groupId":"BG002","value":"306"},{"groupId":"BG003","value":"1137"}]},{"title":"High risk (score ≥3)","measurements":[{"groupId":"BG000","value":"88"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"37"},{"groupId":"BG003","value":"174"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Perception of Anticoagulant Treatment Questionnaire, Part 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second Assessment Compared to Baseline Assessment","description":"Mean Perception of Anticoagulant treatment Questionnaire, part 2 (PACT-Q2) scores, for patients in cohort A, at second assessment compared to baseline assessment. The PACT-Q2 is composed of 3 dimensions covering: convenience (11 items), burden of disease \\& treatment (2 items), \\& anticoagulant treatment satisfaction (7 items). In this outcome the mean convenience \\& satisfaction dimension scores of PACT-Q2 at second assessment (Visit 2) were compared with baseline assessment (Visit 1). Within the PACT-Q2, items for convenience \\& for burden of disease and treatment were reversed (reversed score = 6 - item score), added together \\& rescaled on a 0-100 scale to obtain the convenience dimension score. Items for anticoagulant treatment satisfaction were summed \\& rescaled on 0-100 scale to determine satisfaction score. High scores are more favorable.\n\nPACT-Q2 which were completed more than 1 day after discontinuation of treatment or using incorrect procedure were excluded from analysis.","populationDescription":"The main analysis population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Unit on scale","timeFrame":"Visit 1 (Baseline) and second assessment Visit 2 (7-124 days after initiation on Pradaxa or VKA)","groups":[{"id":"OG000","title":"Cohort A (Switch Patients - Pradaxa)","description":"Patients with non-valvular atrial fibrillation (NVAF), who were treated with a Vitamin K Antagonist (VKA) therapy for at least 3 months for stroke prevention and then switched to 110 or 150 milligram (mg) twice daily dose of Pradaxa."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"}]}],"classes":[{"title":"Convenience dimension score: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"377"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":"21.8"}]}]},{"title":"Convenience dimension score: Second assessment","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"317"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"79.6","spread":"18.1"}]}]},{"title":"Satisfaction dimension score: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"377"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.0","spread":"13.3"}]}]},{"title":"Satisfaction dimension score: Second assessment","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"317"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.2","spread":"14.6"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Convenience dimension score of PACT-Q2 at the second assessment (Visit 2) were compared with the baseline assessment (Visit 1). There was no (confirmatory) hypothesis testing foreseen in a strict statistical sense. Analyses were descriptive in nature and p-values from statistical models were used for exploratory purposes.","nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"p-value of paired t-test compared to baseline","statisticalMethod":"Paired t-test"},{"groupIds":["OG000"],"groupDescription":"Satisfaction dimension score of PACT-Q2 at the second assessment (Visit 2) were compared with the baseline assessment (Visit 1). There was no (confirmatory) hypothesis testing foreseen in a strict statistical sense. Analyses were descriptive in nature and p-values from statistical models were used for exploratory purposes.","nonInferiorityType":"OTHER","pValue":"0.0174","pValueComment":"p-value of paired t-test compared to baseline","statisticalMethod":"Paired t-test"}]},{"type":"PRIMARY","title":"Mean PACT-Q2 Scores, for Patients in Cohort A, at Last Assessment Compared to Baseline Assessment","description":"Mean PACT-Q2 scores, for patients in cohort A, at last assessment compared to baseline assessment. The mean convenience and satisfaction dimension scores of PACT-Q2 at the last assessment (Visit 3) were compared with the baseline assessment (Visit 1). Within the PACT-Q2, items for convenience and for burden of disease and treatment were reversed (reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score. Items for anticoagulant treatment satisfaction were summed and rescaled on a 0-100 scale to determine the satisfaction score. High scores are more favorable.\n\nPACT-Q2 which were completed more than 1 day after discontinuation of treatment or using incorrect procedure were excluded from the analysis.","populationDescription":"The main analysis population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Unit on scale","timeFrame":"Visit 1 (Baseline) and last assessment Visit 3 (125-365 days after initiation on Pradaxa or VKA)","groups":[{"id":"OG000","title":"Cohort A (Switch Patients - Pradaxa)","description":"Patients with non-valvular atrial fibrillation (NVAF), who were treated with a Vitamin K Antagonist (VKA) therapy for at least 3 months for stroke prevention and then switched to 110 or 150 milligram (mg) twice daily dose of Pradaxa."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"}]}],"classes":[{"title":"Convenience dimension score: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"377"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":"21.8"}]}]},{"title":"Convenience dimension score: Last assessment","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"266"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":"16.8"}]}]},{"title":"Satisfaction dimension score: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"377"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.0","spread":"13.3"}]}]},{"title":"Satisfaction dimension score: Last assessment","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"266"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.4","spread":"14.7"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Convenience dimension score of PACT-Q2 at the last assessment (Visit 3) were compared with the baseline assessment (Visit 1). There was no (confirmatory) hypothesis testing foreseen in a strict statistical sense. Analyses were descriptive in nature and p-values from statistical models were used for exploratory purposes.","nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"p-value of paired t-test compared to baseline","statisticalMethod":"Paired t-test"},{"groupIds":["OG000"],"groupDescription":"Satisfaction dimension score of PACT-Q2 at the last assessment (Visit 3) were compared with the baseline assessment (Visit 1). There was no (confirmatory) hypothesis testing foreseen in a strict statistical sense. Analyses were descriptive in nature and p-values from statistical models were used for exploratory purposes.","nonInferiorityType":"OTHER","pValue":"0.0004","pValueComment":"p-value of paired t-test compared to baseline","statisticalMethod":"Paired t-test"}]},{"type":"PRIMARY","title":"Mean PACT-Q2 Scores, for Patients in Cohort B, at Second Assessment Compared Between Treatment Groups","description":"Mean PACT-Q2 scores, for patients in cohort B, at second assessment compared between treatment groups. Convenience dimension score and satisfaction dimension score of PACT-Q2 both range from 0 to 100 with high scores indicate better outcome.\n\nMean PACT-Q2 scores, for patients in Cohort B, were compared between matched Pradaxa® and VKA patients at the second assessment. The mean convenience and satisfaction scores of PACT-Q2 were compared between matched Pradaxa® and VKA patients. Pradaxa® and VKA patients were matched based on propensity scores using a variable ratio, parallel, balanced 2:1, nearest neighbour matching algorithm with a caliper width of 0.05 and without replacement.\n\nPACT-Q2 which were completed more than 1 day after discontinuation of treatment or using incorrect procedure were excluded from the analysis.","populationDescription":"The main analysis population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries and propensity score matched patients.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Unit on scale","timeFrame":"Second assessment Visit 2 (7-124 days after initiation on Pradaxa or VKA)","groups":[{"id":"OG000","title":"Cohort B (New Patients - Pradaxa)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on 110 or 150 mg twice daily Pradaxa"},{"id":"OG001","title":"Cohort B (New Patients - VKA)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on VKA therapy. The choice of vitamin K antagonist and the appropriate dosing was at the discretion of the physician."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"591"},{"groupId":"OG001","value":"343"}]}],"classes":[{"title":"Convenience dimension score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"217"},{"groupId":"OG001","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.4","spread":"14.6"},{"groupId":"OG001","value":"75.1","spread":"19.6"}]}]},{"title":"Satisfaction dimension score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"217"},{"groupId":"OG001","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":"12.7"},{"groupId":"OG001","value":"59.9","spread":"13.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Convenience dimension score of PACT-Q2 for patients in Cohort B, were compared between matched Pradaxa® and VKA patients at the second assessment. There was no (confirmatory) hypothesis testing foreseen in a strict statistical sense. Analyses were descriptive in nature and p-values from statistical models were used for exploratory purposes.","nonInferiorityType":"OTHER","pValue":"0.0423","pValueComment":"p-value of paired t-test compared between matched Pradaxa® and VKA patients","statisticalMethod":"Paired t-test"},{"groupIds":["OG000","OG001"],"groupDescription":"Satisfaction dimension score of PACT-Q2 for patients in Cohort B, were compared between matched Pradaxa® and VKA patients at the second assessment. There was no (confirmatory) hypothesis testing foreseen in a strict statistical sense. Analyses were descriptive in nature and p-values from statistical models were used for exploratory purposes.","nonInferiorityType":"OTHER","pValue":"0.2226","pValueComment":"p-value of paired t-test compared between matched Pradaxa® and VKA patients","statisticalMethod":"Paired t-test"}]},{"type":"PRIMARY","title":"Mean PACT-Q2 Scores, for Patients in Cohort B, at Last Assessment Compared Between Treatment Groups","description":"Mean PACT-Q2 scores, for patients in cohort B, at last assessment compared between treatment groups.\n\nConvenience dimension score and satisfaction dimension score of PACT-Q2 both range from 0 to 100 with high scores indicate better outcome.\n\nMean PACT-Q2 scores, for patients in Cohort B, were compared between matched Pradaxa® and VKA patients at the last assessment. The mean convenience and satisfaction scores of PACT-Q2 were compared between matched Pradaxa® and VKA patients. Pradaxa® and VKA patients were matched based on propensity scores using a variable ratio, parallel, balanced 2:1, nearest neighbour matching algorithm with a caliper width of 0.05 and without replacement.","populationDescription":"The main analysis population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries and propensity score matched patients.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Unit on scale","timeFrame":"Last assessment - Visit 3 (125-365 days after initiation on Pradaxa or VKA)","groups":[{"id":"OG000","title":"Cohort B (New Patients - Pradaxa)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on 110 or 150 mg twice daily Pradaxa"},{"id":"OG001","title":"Cohort B (New Patients - VKA)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on VKA therapy. The choice of vitamin K antagonist and the appropriate dosing was at the discretion of the physician."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"591"},{"groupId":"OG001","value":"343"}]}],"classes":[{"title":"Convenience dimension score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"157"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80.4","spread":"13.6"},{"groupId":"OG001","value":"76.0","spread":"18.9"}]}]},{"title":"Satisfaction dimension score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"157"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.9","spread":"11.6"},{"groupId":"OG001","value":"60.9","spread":"12.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Convenience dimension score of PACT-Q2 for patients in Cohort B, were compared between matched Pradaxa® and VKA patients at the second assessment. There was no (confirmatory) hypothesis testing foreseen in a strict statistical sense. Analyses were descriptive in nature and p-values from statistical models were used for exploratory purposes.","nonInferiorityType":"OTHER","pValue":"0.0287","pValueComment":"p-value of paired t-test compared between matched Pradaxa® and VKA patients","statisticalMethod":"Paired t-test"},{"groupIds":["OG000","OG001"],"groupDescription":"Satisfaction dimension score of PACT-Q2 for patients in Cohort B, were compared between matched Pradaxa® and VKA patients at the second assessment. There was no (confirmatory) hypothesis testing foreseen in a strict statistical sense. Analyses were descriptive in nature and p-values from statistical models were used for exploratory purposes.","nonInferiorityType":"OTHER","pValue":"0.0300","pValueComment":"p-value of paired t-test compared between matched Pradaxa® and VKA patients","statisticalMethod":"Paired t-test"}]},{"type":"PRIMARY","title":"Patient Characterization at Baseline - Categorical Parameters","description":"Categorical parameters of the patient characteristics at baseline included age, gender, Stroke- and/or bleeding related risk factors in medical history (MH), co-morbidities (CoMo), concomitant therapies (CM) and dosing of Pradaxa® (DoP).","populationDescription":"Eligible patients who took the prescribed treatment and without an important protocol violation","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participant","timeFrame":"Baseline (Visit1)","groups":[{"id":"OG000","title":"Cohort A (Switch Patients - Pradaxa)","description":"Patients with non-valvular atrial fibrillation (NVAF), who were treated with a Vitamin K Antagonist (VKA) therapy for at least 3 months for stroke prevention and then switched to 110 or 150 milligram (mg) twice daily dose of Pradaxa."},{"id":"OG001","title":"Cohort B (New Patients - Pradaxa)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on 110 or 150 mg twice daily Pradaxa"},{"id":"OG002","title":"Cohort B (New Patients - VKA)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on VKA therapy. The choice of vitamin K antagonist and the appropriate dosing was at the discretion of the physician."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"classes":[{"title":"< 65 Years","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.1"},{"groupId":"OG001","value":"33.2"},{"groupId":"OG002","value":"53.6"}]}]},{"title":">= 65 and < 75 Years","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40.6"},{"groupId":"OG001","value":"43.3"},{"groupId":"OG002","value":"29.4"}]}]},{"title":">= 75 Years","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.3"},{"groupId":"OG001","value":"23.5"},{"groupId":"OG002","value":"16.9"}]}]},{"title":"Female","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.3"},{"groupId":"OG001","value":"38.6"},{"groupId":"OG002","value":"30.9"}]}]},{"title":"Male","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.7"},{"groupId":"OG001","value":"61.4"},{"groupId":"OG002","value":"69.1"}]}]},{"title":"MH: Thromboembolism","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.3"},{"groupId":"OG001","value":"3.4"},{"groupId":"OG002","value":"1.5"}]}]},{"title":"MH: Cardiovascular Conditions","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.7"},{"groupId":"OG001","value":"5.1"},{"groupId":"OG002","value":"4.4"}]}]},{"title":"MH: Bleedings","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.6"},{"groupId":"OG001","value":"1.0"},{"groupId":"OG002","value":"0.9"}]}]},{"title":"MH: Other Conditions","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.8"},{"groupId":"OG001","value":"3.7"},{"groupId":"OG002","value":"3.8"}]}]},{"title":"CoMo: Thromboembolism","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.8"},{"groupId":"OG001","value":"4.7"},{"groupId":"OG002","value":"7.6"}]}]},{"title":"CoMo: Cardiovascular Conditions","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.1"},{"groupId":"OG001","value":"50.9"},{"groupId":"OG002","value":"40.5"}]}]},{"title":"CoMo: Bleedings","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4"},{"groupId":"OG001","value":"2.5"},{"groupId":"OG002","value":"2.3"}]}]},{"title":"CoMo: Other Conditions","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.9"},{"groupId":"OG001","value":"20.8"},{"groupId":"OG002","value":"17.8"}]}]},{"title":"CM:Antihypertensives","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.5"},{"groupId":"OG001","value":"56.0"},{"groupId":"OG002","value":"47.8"}]}]},{"title":"CM:Lipid modifying agents","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.7"},{"groupId":"OG001","value":"33.5"},{"groupId":"OG002","value":"28.0"}]}]},{"title":"CM:Antithrombotic agents","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.3"},{"groupId":"OG001","value":"9.5"},{"groupId":"OG002","value":"19.8"}]}]},{"title":"CM:Proton pump inhibitors","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.4"},{"groupId":"OG001","value":"13.9"},{"groupId":"OG002","value":"7.9"}]}]},{"title":"CM:Amiodarone","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.4"},{"groupId":"OG001","value":"7.1"},{"groupId":"OG002","value":"5.8"}]}]},{"title":"CM:H2-receptor antagonists","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.7"},{"groupId":"OG001","value":"7.1"},{"groupId":"OG002","value":"2.0"}]}]},{"title":"CM:NSAIDS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8"},{"groupId":"OG001","value":"2.9"},{"groupId":"OG002","value":"1.7"}]}]},{"title":"CM:Verapamil","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"343"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1"},{"groupId":"OG001","value":"1.5"},{"groupId":"OG002","value":"1.7"}]}]},{"title":"DoP:110 mg twice daily","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.1"},{"groupId":"OG001","value":"58.0"}]}]},{"title":"DoP:150 mg twice daily","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"591"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.9"},{"groupId":"OG001","value":"42.0"}]}]}]},{"type":"SECONDARY","title":"Patient Characteristics at Baseline - CHA2DS2-VASc Stroke Risk Score","description":"CHA2DS2-VASc stroke risk score is calculated based on the following conditions: Congestive heart failure, Hypertension, Age (≥ 75), Diabetes Mellitus, Stroke/ Transient Ischaemic Attack (TIA), Vascular disease, Age 65-74, Sex category.\n\nCHA2DS2-VASc stroke risk score may range from 0 to 9 with 0 being the best outcome.","populationDescription":"Eligible patients who took the prescribed treatment and without an important protocol violation","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"unit on scale","timeFrame":"Baseline (Visit1)","groups":[{"id":"OG000","title":"Cohort A (Switch Patients - Pradaxa)","description":"Patients with non-valvular atrial fibrillation (NVAF), who were treated with a Vitamin K Antagonist (VKA) therapy for at least 3 months for stroke prevention and then switched to 110 or 150 milligram (mg) twice daily dose of Pradaxa."},{"id":"OG001","title":"Cohort B (New Patients - Pradaxa)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on 110 or 150 mg twice daily Pradaxa"},{"id":"OG002","title":"Cohort B (New Patients - VKA)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on VKA therapy. The choice of vitamin K antagonist and the appropriate dosing was at the discretion of the physician."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"589"},{"groupId":"OG002","value":"343"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"1.4"},{"groupId":"OG001","value":"2.6","spread":"1.4"},{"groupId":"OG002","value":"2.0","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Patient Characteristics at Baseline - HAS-BLED Bleeding Risk Score","description":"HAS-BLED bleeding risk score is calculated based on the following conditions: Hypertension, Abnormal renal and Hypertension, Abnormal renal and liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly (\\>65 years), Drugs and Alcohol.\n\nHAS-BLED bleeding risk score may range from 0 to 9 with 0 being the best outcome.","populationDescription":"Eligible patients who took the prescribed treatment and without an important protocol violation","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"unit on scale","timeFrame":"Baseline (Visit1)","groups":[{"id":"OG000","title":"Cohort A (Switch Patients - Pradaxa)","description":"Patients with non-valvular atrial fibrillation (NVAF), who were treated with a Vitamin K Antagonist (VKA) therapy for at least 3 months for stroke prevention and then switched to 110 or 150 milligram (mg) twice daily dose of Pradaxa."},{"id":"OG001","title":"Cohort B (New Patients - Pradaxa)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on 110 or 150 mg twice daily Pradaxa"},{"id":"OG002","title":"Cohort B (New Patients - VKA)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on VKA therapy. The choice of vitamin K antagonist and the appropriate dosing was at the discretion of the physician."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"},{"groupId":"OG001","value":"589"},{"groupId":"OG002","value":"343"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"1.1"},{"groupId":"OG001","value":"1.3","spread":"0.9"},{"groupId":"OG002","value":"1.1","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Patient Characteristics at Baseline - Creatinine Clearance","description":"Creatinine clearance at baseline is a measure of the patient's kidney function and is one of the baseline patient characteristics.","populationDescription":"Eligible patients who took the prescribed treatment and without an important protocol violation","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mL/min","timeFrame":"Baseline (Visit1)","groups":[{"id":"OG000","title":"Cohort A (Switch Patients - Pradaxa)","description":"Patients with non-valvular atrial fibrillation (NVAF), who were treated with a Vitamin K Antagonist (VKA) therapy for at least 3 months for stroke prevention and then switched to 110 or 150 milligram (mg) twice daily dose of Pradaxa."},{"id":"OG001","title":"Cohort B (New Patients - Pradaxa)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on 110 or 150 mg twice daily Pradaxa"},{"id":"OG002","title":"Cohort B (New Patients - VKA)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on VKA therapy. The choice of vitamin K antagonist and the appropriate dosing was at the discretion of the physician."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"259"},{"groupId":"OG001","value":"416"},{"groupId":"OG002","value":"189"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.114","spread":"23.147"},{"groupId":"OG001","value":"75.367","spread":"29.028"},{"groupId":"OG002","value":"73.017","spread":"29.179"}]}]}]},{"type":"PRIMARY","title":"Patient Characteristics at Baseline - Duration of Previous VKA Treatment for Cohort A","description":"Duration of continuous VKA treatment for stroke prevention prior to baseline assessment (Cohort A)","populationDescription":"Eligible patients who took the prescribed treatment and without an important protocol violation","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Years","timeFrame":"Baseline (Visit1)","groups":[{"id":"OG000","title":"Cohort A (Switch Patients - Pradaxa)","description":"Patients with non-valvular atrial fibrillation (NVAF), who were treated with a Vitamin K Antagonist (VKA) therapy for at least 3 months for stroke prevention and then switched to 110 or 150 milligram (mg) twice daily dose of Pradaxa."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.28","spread":"3.63"}]}]}]},{"type":"SECONDARY","title":"Mean PACT-Q2 Scores, for Patients in Cohort A, at Last Assessment Compared to Second Assessment","description":"Mean PACT-Q2 scores, for patients in cohort A, at last assessment compared to second assessment.\n\nThe PACT-Q2 is composed of 3 dimensions covering: convenience (11 items), burden of disease and treatment (2 items), and anticoagulant treatment satisfaction (7 items).\n\nThe mean convenience and satisfaction dimension scores of PACT-Q2 at the last assessment (Visit 3)were compared with the second assessment (Visit 2). Within the PACT-Q2, items for convenience and for burden of disease and treatment were reversed (reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score. Items for anticoagulant treatment satisfaction were summed and rescaled on a 0-100 scale to determine the satisfaction score.","populationDescription":"The main analysis population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Unit on scale","timeFrame":"Second assessment - Visit 2 (7-124 days after initiation on Pradaxa or VKA) and last assessment - Visit 3 (125-365 days after initiation on Pradaxa or VKA)","groups":[{"id":"OG000","title":"Cohort A (Switch Patients - Pradaxa)","description":"Patients with non-valvular atrial fibrillation (NVAF), who were treated with a Vitamin K Antagonist (VKA) therapy for at least 3 months for stroke prevention and then switched to 110 or 150 milligram (mg) twice daily dose of Pradaxa."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"379"}]}],"classes":[{"title":"Convenience dimension score (Visit 2)","categories":[{"measurements":[{"groupId":"OG000","value":"79.6","spread":"18.1"}]}]},{"title":"Convenience dimension score (Visit 3)","categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":"16.8"}]}]},{"title":"Satisfaction dimension score (Visit 2)","categories":[{"measurements":[{"groupId":"OG000","value":"63.2","spread":"14.6"}]}]},{"title":"Satisfaction dimension score (Visit 3)","categories":[{"measurements":[{"groupId":"OG000","value":"64.4","spread":"14.7"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Convenience dimension score of PACT-Q2 for patients in Cohort A, were compared between second assessment (Visit 2) and last assessment (Visit 3). There was no (confirmatory) hypothesis testing foreseen in a strict statistical sense. Analyses were descriptive in nature and p-values from statistical models were used for exploratory purposes.","nonInferiorityType":"OTHER","pValue":"0.1234","pValueComment":"p-value of paired t-test compared between second assessment (Visit 2) and last assessment (Visit 3)","statisticalMethod":"Paired t-test"},{"groupIds":["OG000"],"groupDescription":"Satisfaction dimension score of PACT-Q2 for patients in Cohort A, were compared between second assessment (Visit 2) and last assessment (Visit 3). There was no (confirmatory) hypothesis testing foreseen in a strict statistical sense. Analyses were descriptive in nature and p-values from statistical models were used for exploratory purposes.","nonInferiorityType":"OTHER","pValue":"0.9740","pValueComment":"p-value of paired t-test compared between second assessment (Visit 2) and last assessment (Visit 3)","statisticalMethod":"Paired t-test"}]},{"type":"SECONDARY","title":"Description of Perception of Anticoagulant Treatment Questionnaire, Part 1 (PACT-Q1) Items at Baseline for Cohort B","description":"For Cohort B, scores of PACT-Q1 at baseline were summarised descriptively.\n\nThe PACT-Q1 is composed of a single dimension (7 items) covering the expectations of patients regarding their anticoagulant treatment and is to be administered before treatment initiation.\n\nThe PACT-Q1 scores ranged from 1 (Not at all) to 5 (Extremely/Completely/ Very much).","populationDescription":"The main analysis population consisted of all eligible patients (that is, all patients who took the prescribed treatment and without an important protocol violation) from all participating countries. PACT-Q1 data which were collected after the first dose or using incorrect procedure were excluded from the summary.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Unit on scale","timeFrame":"Baseline (Visit1)","groups":[{"id":"OG000","title":"Cohort B (New Patients - Pradaxa)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on 110 or 150 mg twice daily Pradaxa"},{"id":"OG001","title":"Cohort B (New Patients - VKA)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on VKA therapy. The choice of vitamin K antagonist and the appropriate dosing was at the discretion of the physician."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"580"},{"groupId":"OG001","value":"340"}]}],"classes":[{"title":"A1 - Confidence in prevention of blood clots","categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"1.0"},{"groupId":"OG001","value":"3.3","spread":"1.0"}]}]},{"title":"A2 - Expectations of symptom relief","categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"0.9"},{"groupId":"OG001","value":"3.3","spread":"1.0"}]}]},{"title":"A3 - Expectations of side effects","categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"1.0"},{"groupId":"OG001","value":"2.6","spread":"1.0"}]}]},{"title":"A4 - Importance of ease of use","categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"0.9"},{"groupId":"OG001","value":"3.5","spread":"1.0"}]}]},{"title":"A5 - Worries about making mistakes","categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"1.2"},{"groupId":"OG001","value":"2.5","spread":"1.2"}]}]},{"title":"A6 - Importance of independency","categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"0.9"},{"groupId":"OG001","value":"3.7","spread":"1.0"}]}]},{"title":"A7 - Worries about cost","categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"1.2"},{"groupId":"OG001","value":"2.6","spread":"1.2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From the first administration of study medication until end of the study, up to 406 days","description":"In this non-interventional study, a systematic collection of safety data was neither planned nor performed. The focus was on non-serious and serious adverse drug reactions to Pradaxa® and VKA and on fatal adverse events (AEs), that is, AEs that were not considered to have a reasonable possibility to be causally related to the prescribed anticoagulant treatment were only collected when fatal","eventGroups":[{"id":"EG000","title":"Cohort A (Switch Patients - Pradaxa)","description":"Patients with non-valvular atrial fibrillation (NVAF), who were treated with a Vitamin K Antagonist (VKA) therapy for at least 3 months for stroke prevention and then switched to 110 or 150 milligram (mg) twice daily dose of Pradaxa.","deathsNumAffected":1,"deathsNumAtRisk":379,"seriousNumAffected":5,"seriousNumAtRisk":379,"otherNumAffected":0,"otherNumAtRisk":379},{"id":"EG001","title":"Cohort B (New Patients - Pradaxa)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on 110 or 150 mg twice daily Pradaxa","deathsNumAffected":0,"deathsNumAtRisk":591,"seriousNumAffected":1,"seriousNumAtRisk":591,"otherNumAffected":0,"otherNumAtRisk":591},{"id":"EG002","title":"Cohort B (New Patients - VKA)","description":"Newly diagnosed NVAF patients who were not previously treated with an anticoagulant for the prevention of stroke, and were initiated on VKA therapy. The choice of vitamin K antagonist and the appropriate dosing was at the discretion of the physician.","deathsNumAffected":0,"deathsNumAtRisk":343,"seriousNumAffected":6,"seriousNumAtRisk":343,"otherNumAffected":0,"otherNumAtRisk":343}],"seriousEvents":[{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":379},{"groupId":"EG001","numAffected":0,"numAtRisk":591},{"groupId":"EG002","numAffected":2,"numAtRisk":343}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":379},{"groupId":"EG001","numAffected":0,"numAtRisk":591},{"groupId":"EG002","numAffected":1,"numAtRisk":343}]},{"term":"Diverticulum intestinal haemorrhagic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":379},{"groupId":"EG001","numAffected":0,"numAtRisk":591},{"groupId":"EG002","numAffected":0,"numAtRisk":343}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":379},{"groupId":"EG001","numAffected":0,"numAtRisk":591},{"groupId":"EG002","numAffected":0,"numAtRisk":343}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":379},{"groupId":"EG001","numAffected":0,"numAtRisk":591},{"groupId":"EG002","numAffected":0,"numAtRisk":343}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":379},{"groupId":"EG001","numAffected":1,"numAtRisk":591},{"groupId":"EG002","numAffected":0,"numAtRisk":343}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":379},{"groupId":"EG001","numAffected":0,"numAtRisk":591},{"groupId":"EG002","numAffected":0,"numAtRisk":343}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":379},{"groupId":"EG001","numAffected":0,"numAtRisk":591},{"groupId":"EG002","numAffected":0,"numAtRisk":343}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":379},{"groupId":"EG001","numAffected":0,"numAtRisk":591},{"groupId":"EG002","numAffected":1,"numAtRisk":343}]},{"term":"Metabolic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":379},{"groupId":"EG001","numAffected":0,"numAtRisk":591},{"groupId":"EG002","numAffected":0,"numAtRisk":343}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":379},{"groupId":"EG001","numAffected":0,"numAtRisk":591},{"groupId":"EG002","numAffected":1,"numAtRisk":343}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":379},{"groupId":"EG001","numAffected":0,"numAtRisk":591},{"groupId":"EG002","numAffected":0,"numAtRisk":343}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":379},{"groupId":"EG001","numAffected":0,"numAtRisk":591},{"groupId":"EG002","numAffected":1,"numAtRisk":343}]},{"term":"Hypovolaemic shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":379},{"groupId":"EG001","numAffected":0,"numAtRisk":591},{"groupId":"EG002","numAffected":0,"numAtRisk":343}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"The choice of anticoagulant treatment was at the discretion of the treating physician and independent from study participation. The planned between-country comparisons of study results could not be performed or were not meaningful when performed."},"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Boehringer Ingelheim, Call Center","organization":"Boehringer Ingelheim","email":"clintriage.rdg@boehringer-ingelheim.com","phone":"1-800-243-0127"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-01-02","uploadDate":"2018-12-11T07:57","filename":"SAP_000.pdf","size":193896},{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2016-01-25","uploadDate":"2018-12-11T07:57","filename":"Prot_001.pdf","size":659440}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Turkey","Vietnam"]},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000014812","term":"Vitamin K"},{"id":"D000069604","term":"Dabigatran"}],"ancestors":[{"id":"D000014815","term":"Vitamins"},{"id":"D000018977","term":"Micronutrients"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"},{"id":"D000000933","term":"Antifibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000006490","term":"Hemostatics"},{"id":"D000003029","term":"Coagulants"}],"browseLeaves":[{"id":"M17245","name":"Vitamin K","asFound":"Black","relevance":"HIGH"},{"id":"M17248","name":"Vitamins","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M490","name":"Dabigatran","asFound":"4 hours","relevance":"HIGH"},{"id":"M20699","name":"Micronutrients","relevance":"LOW"},{"id":"M16575","name":"Trace Elements","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3942","name":"Antifibrinolytic Agents","relevance":"LOW"},{"id":"M9266","name":"Hemostatics","relevance":"LOW"},{"id":"M5949","name":"Coagulants","relevance":"LOW"},{"id":"T481","name":"Vitamin K","asFound":"Black","relevance":"HIGH"},{"id":"T450","name":"Menaquinone","relevance":"LOW"},{"id":"T449","name":"Menadione","relevance":"LOW"},{"id":"T452","name":"Naphthoquinone","relevance":"LOW"},{"id":"T458","name":"Phylloquinone","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"Vi","name":"Vitamins"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":true}